Answers are grounded in this paper and cite their sources.
Retrospective cohort analysis shows similar outcomes for GPi-DBS and STN-DBS in dystonia patients, suggesting both are effective options.
Background: Although deep brain stimulation (DBS) targeting the globus pallidus internus (GPi) or the subthalamic nucleus (STN) has shown efficacy for Meige syndrome (MS), there is limited comparative evidence available. Methods: This retrospective cohort study consecutively enrolled patients with primary MS who underwent bilateral GPi-DBS or STN-DBS at our center between March 2015 and February 2025. Propensity score matching (PSM, 1.5:1) was employed to balance baseline covariates. The primary outcomes were improvements in the Burke-Fahn-Marsden Dystonia Rating Scale movement subscore (BFMDRS-M) at 3-month (short-term) and at the final follow-up (long-term). Additionally, stimulation parameters, programming adjustments, and adverse events were analyzed. Results: The study cohort comprised 254 eligible patients (GPi-DBS: 176; STN-DBS: 78), with 14 patients (4.8%) lost to follow-up. The overall cohort consisted of 178 females (70.1%) with a mean surgical age of 57.7 ± 8.6 years. After PSM, 157 patients were matched (89 GPi-DBS, 68 STN-DBS). At 3-month follow up, the mean improvement rate of BFMDRS-M total score was 51.0% (95% Confidence interval (CI): 46.7%, 55.3%) for GPi-DBS and 54.6% (95% CI: 49.3%, 59.8%) for STN-DBS, with no significant intergroup difference (P = 0.235). After a mean follow-up of 42.4 ± 23.6 months, the mean improvement was 61.0% (95% CI: 56.4–65.5%) for GPi-DBS and 65.2% (95% CI: 59.2–71.1%) for STN-DBS, again indicating no significant difference (P = 0.192). STN-DBS required lower stimulation parameters but significantly more programming adjustments than GPi-DBS (mean sessions: 5.49 vs. 4.33; P< 0.001). Adverse event incidence was similar between groups (GPi-DBS vs. STN-DBS: 5.4% vs. 3.6%; P = 0.731). Conclusions: Both GPi-DBS and STN-DBS provided significant and sustained motor symptom improvement in refractory MS, with no statistically significant difference between groups.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: